Novartis's trial setbacks are negatively affecting market sentiment and causing a stock decline.
2 reports, 2 independent
Updated Sep 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novartis's trial setbacks are negatively affecting market sentiment and causing a stock decline.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novartis
Swiss-American multinational pharmaceutical corporation
Related events
- Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
- Novartis' trial results are impacting Royalty Pharma's investment decisions.
- Novartis shares declined due to drug failure amidst geopolitical concerns regarding Iran and Oman, while Infineon benefited from an upgrade.
- Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.